Speaking about the agreement, Leonard Schleifer, president and CEO of Regeneron said: "As we continue to advance and expand our research efforts in immuno-oncology, the acquisition of Checkmate will add a promising new modality to Regeneron's toolkit of potential approaches for difficult-to-treat cancers. It works by pairing two complementary mechanisms, which when combined, have a unique capability to drive a strong systemic anti-tumour T-cell response. Vidutolimod is administered into the tumour and is thought to activate and spread anti-tumour T cells and initiate tumour regression as a monotherapy in patients whose tumours previously advanced on PD-1 checkpoint inhibition.
Regeneron checkmate Activator#
Regeneron has announced that it will acquire Checkmate Pharmaceuticals in a proposed deal of around $250m.Ĭheckmate is a clinical stage biotech company, focused on developing its technologies to use the power of human immune systems against cancer.Īs part of the acquisition, Regeneron will take on Checkmate's lead investigational candidate, vidutolimod, an investigational immune activator which has the potential to be used in multiple types of tumour.
0 kommentar(er)
